“DFD-03 (0.1% Tazarotene), Twice-Daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product With Once-Daily Overnight Application”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s46. Accessed May 18, 2025. https://skin.dermsquared.com/skin/article/view/199.